MAP2K2 Antibody, Biotin conjugated

1. Data show that SAM and SH3 domain containing 1 protein (SASH1) binds with mitogen-activated protein kinase kinase 2 (MAP2K2), and SASH1 mutations promote binding between SASH1 and MAP2K2. PMID:28382689
2. findings demonstrate the interaction of tRNA with MEK2 in pancreatic cancer cells and suggest that tRNA may impact MEK2 activity in cancer cells PMID:27301426
3. MEK2 was essential for the phosphorylation of MKK3/MKK6 and p38 MAPK that directly impacted on cyclin D1 expression. PMID:27181679
4. High MEK2 expression is associated with inflammation. PMID:28178421
5. there were significant decreases in intercellular adhesion molecules 1 (ICAM1), ezrin (EZR), mitogen-activated protein kinase kinase 2 (MAP2K2), and nitric oxide synthase 3 (NOS3) gene expressions in metabolic syndrome patients. PMID:26956845
6. The patient showed a paternally inherited 16p13.11 microduplication and a de novo 19p13.3 microdeletion involving the mitogen-activated protein kinase kinase 2 gene (MAP2K2), in which mutations cause the cardio-facio-cutaneous (CFC) syndrome PMID:27751966
7. We report on a fourth familial case with transmission of CFC syndrome from father to son due to a novel heterozygous sequence change c.376A>G (p.N126D) in exon 3 of MEK2 gene. PMID:25487361
8. MK2 attenuates dendritic cell-mediated Th1 differentiation and autoimmune encephalomyelitis. PMID:26078274
9. Our cohort of seven individuals with MEK2 deletions has overlapping features associated with RASopathies. PMID:23379592
10. Both ACE inhibition and MEK1/2 inhibition have beneficial effects on left ventricular function in Lmna(H222P/H222P) mice and both drugs together have a synergistic benefit when initiated after the onset of left ventricular dysfunction. PMID:25218145
11. we report familial patients with multiple cafe au lait spots and Noonan syndrome-like facial features who carried mutations in MAP2K2. PMID:24311457
12. osteosarcoma patients whose tumors expressed pMEK2 had a poorer clinical outcome than those whose tumors did not. PMID:22935974
13. MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2. PMID:22895183
14. E-cadherin is necessary for localization of DLG1 but not phosphorylated MEK2 to the midbody ring during cytokinesis. PMID:22185284
15. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. PMID:21969554
16. hDlg acts as a MEK2-specific scaffold protein for the ERK signaling pathway. PMID:21615688
17. Data report the full-length structure of MEK2 obtained by homology modeling and molecular dynamics simulations. PMID:21509657
18. In the absence of other MKK, MEK2 is sufficient for SK-MEL-28 cell proliferation and anchorage-dependent growth. PMID:21365009
19. ETS1 is probably mediating high CIP2A expression in human cancers with increased EGFR-MEK1/2-ERK pathway activity PMID:21445343
20. familial inheritance of cardiofaciocutaneous syndrome with MEK2 mutation PMID:21178588
21. MEK1 and MEK2 play a part in the induction of the proinflammatory cytokine. PMID:20837746
22. This first reported case of a vertically transmitted functional Cardio-facio-cutaneous syndrome MEK mutation. PMID:20358587
23. MEK2 activity ad dual-phosphorylation were undetectable in expanding and self-renewing hematopoietic progenitors (HP). Adding IL-3, inducing maturation and cell death in HP, led to sustained high levels of MEK2 activity and dual-phosphorylation. PMID:12032872
24. MK2 phosphorylates TSC2, which creates a 14-3-3 binding site and thus regulates the cellular function of the TSC2 tumor suppressor protein PMID:12582162
25. MAPK activated protein kinase-2 mediates both ERK- and p38 MAPK-dependent neutrophil responses. PMID:14499342
26. HuR and MK2 in regulating the expression of uPA and uPAR genes at the posttranscriptional level PMID:14517288
27. Results suggest a physiological link between beta-dystroglycan and mitogen-activated protein kinase kinase 2 (MEK2), and localize MEK with dystroglycan in membrane ruffles. PMID:15071496
28. The ability of constitutively-active human MEK2 to stimulate ERK phosphorylation and to induce the neoplastic transformation of NIH 3T3 cells required the integrity of the D-site was found. PMID:15979847
29. These data suggest a role for mitochondrially generated reactive oxygen species and Ca(2+) in the redox cell signaling path-ways, leading to ERK activation and adaptation of the pathological stress mediated by oxidized lipids such as lysoPC. PMID:16651638
30. 3 novel mutations for MEK2 (L46_E55del, K61T, A62P) were identified in 15 patients with cardio-facio-cutaneous syndrome. PMID:17704260
31. Spectrum of MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations PMID:19156172
32. MEK2 interacts with ERK1. This interaction is mediated via a conserved N-terminal docking site in MEK2. PMID:11134045

Show More

Hide All

HGNC: 6842

UNIGENE: Hs.465627

KEGG: hsa:5605

STRING: 9606.ENSP00000262948

OMIM: 601263